About Us

Jeff Davidson, B.S. Ch. E., MBA – Chief Operating Officer 

​

Co-founder who raised $15.5 million for Pendrea; led development of the product pipeline, cGMP manufacturing, clinical and partnering programs. Previously, Founder of Life Sciences PA, a trade industry organization with over 800 members. Also Founder and Executive Director of BIO’s Biotechnology Institute.

​

Daniel Vlock, MD., Chief Medical Officer

 

A board certified medical oncologist with a distinguished academic career (Yale, Harvard, Cornell) and 25+ years of pharmaceutical industry experience. He has held Director and Vice President positions at Boehringer Ingelheim, Pharmacia, Ariad and other biopharmaceutical companies before founding his own company, Alopexx Enterprises, LLC. That company successfully licensed its technology to Sanofi for $375 million. Dr. Vlock has had responsibility for
numerous clinical development programs including pivotal, multi-center Phase III studies.

​

James Sharpe, BS Chem, MBA -- Chief Business Officer

 

Prior positions include Founder and CEO of an immuno-oncology company, President of a drug discovery company, COO of a drug delivery company and CEO of a public biopharm company. He also served as Director of Marketing for Centocor, Inc., Director of Business Development for Benzon Pharma A/S, and Director, Strategic Planning for the $1 Billion Health Sciences
Division of Eastman Kodak Co.

​

James Adair, Ph.D. - Chief Science Officer

​

Co-founder, Professor of Material Science, Penn State University, developer of NanoJacket technologies and a leading nanoparticle expert.

​

Chris Prior, Ph.D. – Senior Advisor

 

35+ years in pharmaceutical development; 25 INDs; 4 product approvals; founded and sold two biopharma companies (Principia, BioRexis) with exits exceeding $500 million; Raised $75 million as CEO of PhaseBIO; took Innovate Biopharmaceuticals 4 public; director of R&D at Aventis (now Sanofi), senior product development scientist at Biogen (7th
employee).